


## SUPPLEMENTAL MATERIAL

**Supplemental Figure S1: Medical Therapies for COVID-19**

Use of glucocorticoids, hydroxychloroquine, convalescent plasma, remdesivir, and tocilizumab  
from March 2020 to December 2021




**Supplemental Figure S2: Cardiovascular Outcomes Among Hospitalized Patients with COVID-19**


Panel A. Incidence of myocardial infarction.


Panel B. Incidence of stroke.


Panel C. Incidence of new heart failure.

Panel D. Incidence of pulmonary embolism (PE) and deep vein thrombosis (DVT).












**Supplemental Figure S3: Use of Mechanical Ventilation Among Hospitalized Patients with COVID-19**

Proportion of patients who were placed on mechanical ventilation. P-values shown are from the unadjusted trend analysis.



**Supplemental Figure S4: Use of Echocardiography in Patients Admitted with COVID-19**

Proportion of patients who underwent an echocardiogram while admitted.

